NoAb BioDiscoveries (www.noabbiodiscoveries.com) is a research organization that provides superior scientific procedures for the selection of new drug candidates. It helps to shape and optimize the drug discovery process through specialized and proprietary research services that focus on lead selection and optimization. These services include in vivo pharmacokinetics (PK) studies, in vitro ADME assays, bioanalytical services and gene expression assays. NoAb BioDiscoveries is one of the cutting edge leaders in the drug discovery market because it continuously evaluates and improves on existing protocols to deliver innovative tools and technologies that facilitate success and accelerate timelines in producing optimal and viable clinical candidates. These advanced research tools better characterize the pharmacokinetic properties of new drug candidates, optimizing the selection of leads. In addition to the vital information generated by in vitro ADME profiling, drug discovery requires the extrapolation of this data to in vivo situations and NoAb BioDiscoveries offers a range of in vivo PK studies that include:
" Carotid artery and jugular vein catheterized rats with intra-duodenal dosing.
" Carotid artery, jugular vein and bile duct catheterized rats and guinea pigs.
" Hepatoportal vein catheterized rats.
" Serial collection of plasma and cerebrospinal fluid (CSF) in freely moving rats.
Microdialysis and cerebrospinal fluid collection are two specialized in vivo PK protocols on offer. The team of scientists at NoAb BioDiscoveries designs the best strategies and protocols for any drug discovery needs and skillfully designs and performs both standard procedures and specialized protocols such as microdialysis according to customer specifications. Microdialysis is a sampling technique that allows the in vivo measurement of endogenous and exogenous substances in the extracellular fluid surrounding a dialysis probe implanted into an organ or tissue. It is an important in vivo technique to assess central nervous system (CNS) penetration for drugs intended to treat neurological or psychopathic disorders where the therapeutic agents reside mainly within the CNS. Drug penetration into the CNS is of vital importance to characterize a new drug compound for potential efficacy and/or toxicity.
A typical microdialysis study at the NoAb BioDiscoveries' research facility located in the heart of one of North America's key biotech hubs, involves the implantation of two dialysis probes: one into a specific brain area of interest and the other into the jugular vein. At NoAb BioDiscoveries, the probes are implanted into freely moving rats. The brain probe allows sampling of the brain interstitial fluid concentrations of the drug candidate at its predicted site of action while the jugular vein allows sampling of the unbound concentration of the drug candidate in the plasma. LC-MS/MS is then used to determine the brain and plasma concentrations of the dialysates and the information obtained can be used to compare brain to plasma concentrations and generate plasma concentration versus time profiles for evaluation of the transport characteristics of the drug candidate across the blood brain barrier (BBB).
Such innovative research tools as microdialysis have enabled NoAb BioDiscoveries to continue to offer premier drug discovery services to its clients. The organization is committed to using innovation to build the future of drug discovery research and is renowned for its quality, efficiency and timeliness. You can reduce the costs associated with drug discovery research and the time required to market a new drug while maximizing success by trusting your lead selection and optimization to the experts at NoAb BioDiscoveries!
